𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A simple method for the preparation of 123I and 125I labeled iodobenzodiazepines

✍ Scribed by Bill J. McBride; Ronald M. Baldwin; Janice M. Kerr; Jiann-Long Wu

Publisher
Elsevier Science
Year
1991
Weight
320 KB
Volume
42
Category
Article
ISSN
0883-2889

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Preparation of ω-123I-labelled fatty aci
Preparation of ω-123I-labelled fatty acids by 123I-for-Br exchange: Comparison of three methods
✍ Peter Laufer; Hans-Jürgen MacHulla; Helmut Michael; Heinz Hubert Coenen; Afaf Sa 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 French ⚖ 361 KB

## Abstract Long chain ω‐^123^‐I‐labelled fatty acids such as 16‐I‐hexadecanoic‐, 17‐I‐heptadecanoic‐, and 16‐I‐hexadec‐9‐enoic acid have been prepared without adding carrier by nucleophilic ^123^I‐for‐Br exchange in acetone, in the melt, and by use of phase transfer catalysts in non‐polar solvents

I-125 and I-123 labelled iodobenzyl brom
I-125 and I-123 labelled iodobenzyl bromide, a useful alkylating agent for radiolabelling biologically important molecules
✍ Alan A. Wilson; Robert F. Dannals; Hayden T. Ravert; H. Donald Burns; Henry N. W 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 French ⚖ 426 KB

The radioiodination of 4-trimethylsilylbenzyl bromide in acetic acid with no carrier added 1-125 and 1-123 iodide ion and N-chlorosuccinimide (NCS) is a rapid, high yielding process which produces high specific activity 4-[I-125 or I-123liodobenzyl bromide. alkylating agent has been efficiently reac

Preparation of [123I]- and [125I]epidepr
Preparation of [123I]- and [125I]epidepride: A dopamine D-2 receptor antagonist radioligand
✍ J. A. Clanton; T. de Paulis; D. E. Schmidt; M. S. Ansari; R. G. Manning; R. M. B 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 French ⚖ 412 KB

## Abstract (__S__)‐(−)‐__N__‐[(1‐ethyl‐2‐pyrrolidinyl)methyl]‐5‐[^123^I]iodo‐2,3‐dimethoxybenzamide (TDP 517) (proposed generic name, [^123^I]epidepride) is the iodine‐123 substituted analogue of isoremoxipride (FLB 457), both of which are very potent dopamine D‐2 antagonists (epidepride K~D~ 0.02